Pluripotent stem cells for cell replacement therapy of diabetes

Deutsche medizinische Wochenschrift
Ortwin Naujok, Sigurd Lenzen

Abstract

The use of pluripotent stem cells (PSCs) harbours great potential for a future use in the cell replacement therapy of diabetes mellitus. The in vitro differentiation of human or mouse embryonic stem cells has yielded pancreatic progenitor cells, but not authentic insulin-producing beta cells. Induced pluripotent cells are a class of a pluripotent stem cells potentially suited as a cell source for cell replacement therapy. These patient specific pluripotent cells are generated by reprogramming but unfortunately accumulate genetic and epigenetic errors during reprogramming, precluding their use for therapeutic purposes in humans.

Citations

Sep 28, 2012·Clinical and Experimental Medicine·Patricia Gálvez MartínBeatriz Clares Naveros

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Related Papers

Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation
Anahita ShaerMehrdad Shariati
Science in China. Series C, Life Sciences
DongHui ZhangHongkui Deng
Molecular Therapy : the Journal of the American Society of Gene Therapy
Ortwin NaujokSigurd Lenzen
© 2021 Meta ULC. All rights reserved